Non-alcoholic fatty liver disease and antiviral therapy in hepatitis C.

Sir, I have read the excellent paper by Shifflet and Wu.1 Watanabe et al reported that several metabolic disturbances, such as obesity, insulin resistance, and hepatic steatosis, are significant risk factors for decreased sustained virologic response to interferon and ribavirin combination antiviral therapy in chronic hepatitis C patients.2 It should be noted, for completeness, the influence of non-alcoholic fatty liver disease (NAFLD) on post liver transplantation (LT) antiviral treatment. It is well known that the natural history of recurrent hepatitis C is accelerated after LT. Hepatitis C driven fibrosis response in the allograft leads to the development of graft cirrhosis in approximately 25% of recipients after a follow-up of 5–10 years. More than 10% of patients who undergo transplantation for hepatitis C cirrhosis eventually require retransplantation for hepatitis C related graft failure.3 In relation to organ shortage, Llado et al affirmed that retransplantation is not an option for recurrent hepatitis C cirrhosis after LT.4 For this reason, it is mandatory to protect in the best way the graft by treating with antiviral therapy for recurrent hepatitis C.5 In a substantial proportion of infected recipients, liver injury remains mild despite high viral burden. Several factors have been clearly shown to be associated with fibrosis progression rate. Metabolic conditions and steatosis are emerging as independent cofactors of fibrogenesis. Machicao et al suggested that allograft steatosis is a common occurrence after orthotopic liver transplantation (metabolic alterations, immunosuppression) and is independent of concomitant HCV infection.6 Till now, in our experience, there is evidence for the importance of parameters such as body mass index (BMI, kg/m2), cholesterol (mg/dL), triglycerides (TG, ng/mL) and hepatic percentage of steatosis in response to therapy with pegylated interferon (PEG-IFN) alfa-2b and ribavirin in patients with recurrent hepatitis C after LT.7 Response to therapy was evaluated in relation to virologic response (HCV-RNA assay was performed at 1, 3, 6, 12 and 18 months): sustained virologic response (SVR) was defined as the absence of serum HCV-RNA (virologic remission) and serum alanine aminotransferase (ALT) activity within the reference range for at least 6 months after; sustained biochemical response (SBR) was defined as a decrease in serum ALT activity to within the reference range but with reappearance or persistently detectable serum HCV-RNA; nonresponse (NR) was defined as persistence/relapse at the end of therapy of HCV-RNA and no decrease in ALT activity or relapse at the end of therapy. Ten patients (31.2%) stopped therapy for side effects, SVR was observed in six cases (6/22, 27.2%), SBR in seven cases (7/22, 31.8%) and NR in nine cases (9/22, 40.9%).

• Publication year

  2009

• Venue

  Journal of the Formosan Medical Association = Taiwan yi zhi

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0929-6646(09)60062-0PMID 19293044
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Non-alcoholic steatohepatitis: an overview.

  2009cited by this paper
• Liver diseases and metabolic syndrome

  2008cited by this paper
• Prolonged Hepatitis B surface antigen positivity in Hepatitis B vaccine recipients.

  2006cited by this paper
• Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection

  2006cited by this paper
• Pegylated interferon (PEG-IFN) alfa-2b and ribavirin for recurrent hepatitis C (genotype 1) after liver transplantation: relationship with steatosis.

  2006cited by this paper
• Is retransplantation an option for recurrent hepatitis C cirrhosis after liver transplantation?

  2005cited by this paper
• Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1

  2005cited by this paper
• Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation

  2004cited by this paper
• Recurrent hepatitis C in transplanted patients: more questions than answers.

  2003cited by this paper
• Treatment for recurrent hepatitis C.

  2003cited by this paper
• Treatment of recurrent hepatitis C

  2002cited by this paper

• No citing papers are available for this paper.